EUVIMEDEUVIMED entdecken
Open Access

An mTORC1‐Dependent Mouse Model for Cardiac Sarcoidosis

Carlos Bueno-Beti iD, Clarice X Lim iD, Alexandros Protonotarios iD, Petra Lujza Szabo iD, Joseph Westaby iD, Mario Mazic iD, Mary N Sheppard iD, Elijah Behr iD, Ouafa Hamza iD, Attila Kiss, Bruno K Podesser iD, Markus Hengstschläger iD und 2 weitere

Journal of the American Heart Association · 2023

DOI: 10.1161/jaha.123.030478 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Heart Association, 2023. Verfasst von Carlos Bueno-Beti und 13 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Cardiology Academic Group, Molecular and Clinical Research Science Institute St George's University of London London United Kingdom. Hauptthemen laut MEDLINE: Mechanistic Target of Rapamycin Complex 1, Sarcoidosis, Cardiomyopathies. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Wellcome Trust, British Heart Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Sarcoidosis is an inflammatory, granulomatous disease of unknown cause affecting multiple organs, including the heart. Untreated, unresolved granulomatous inflammation can lead to cardiac fibrosis, arrhythmias, and eventually heart failure. Here we characterize the cardiac phenotype of mice with chronic activation of mammalian target of rapamycin (mTOR) complex 1 signaling in myeloid cells known to cause spontaneous pulmonary sarcoid‐like granulomas. Methods and Results The cardiac phenotype of mice with conditional deletion of the tuberous sclerosis 2 ( TSC2 ) gene in CD11c + cells (TSC2 fl/fl CD11c‐Cre; termed TSC2 KO ) and controls ( TSC2 fl/fl ) was determined by histological and immunological stains. Transthoracic echocardiography and invasive hemodynamic measurements were performed to assess myocardial function. TSC2 KO animals were treated with either everolimus, an mTOR inhibitor, or Bay11‐7082, a nuclear factor‐kB inhibitor. Activation of mTOR signaling was evaluated on myocardial samples from sudden cardiac death victims with a postmortem diagnosis of cardiac sarcoidosis. Chronic activation of mTORC1 signaling in CD11c + cells was sufficient to initiate progressive accumulation of granulomatous infiltrates in the heart, which was associated with increased fibrosis, impaired cardiac function, decreased plakoglobin expression, and abnormal connexin 43 distribution, a substrate for life‐threatening arrhythmias. Mice treated with the mTOR inhibitor everolimus resolved granulomatous infiltrates, prevented fibrosis, and improved cardiac dysfunction. In line, activation of mTOR signaling in CD68 + macrophages was detected in the hearts of sudden cardiac death victims who suffered from cardiac sarcoidosis.

Conclusions

To our best knowledge this is the first animal model of cardiac sarcoidosis that recapitulates major pathological hallmarks of human disease. mTOR inhibition may be a therapeutic option for patients with cardiac sarcoidosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mechanistic Target of Rapamycin Complex 1SarcoidosisCardiomyopathiesAnimalsHumansMiceDeath, Sudden, CardiacDisease Models, AnimalEverolimusFibrosisMammalsMultiprotein ComplexesMyocarditisSirolimusTOR Serine-Threonine KinasesTuberous Sclerosis Complex 2 ProteinTumor Suppressor Proteins

Stichwörter der Autor:innen

cardiac sarcoidosisfibrosisheartmTORC1mouse modelsarcoidosis

Substanzen

EverolimusMechanistic Target of Rapamycin Complex 1Multiprotein ComplexesSirolimusTOR Serine-Threonine KinasesTuberous Sclerosis Complex 2 ProteinTumor Suppressor Proteins

Autor:innen und Institutionen

  • Clinical Cardiology Academic Group, Molecular and Clinical Research Science Institute St George's University of London London United Kingdom.
  • Center for Pathobiochemistry and Genetics Medical University of Vienna Vienna Austria.
  • Institute of Cardiovascular Science, Clinical Science Research Group University College London London United Kingdom.
  • Center for Biomedical Research Medical University of Vienna Vienna Austria.

ORCID-Profile: Carlos Bueno-Beti, Clarice X Lim, Alexandros Protonotarios, Petra Lujza Szabo, Joseph Westaby, Mario Mazic, Mary N Sheppard, Elijah Behr, Ouafa Hamza, Bruno K Podesser, Markus Hengstschläger, Thomas Weichhart, Angeliki Asimaki

Förderung

  • Wellcome Trust
  • British Heart Foundation

Zitieren

APA

Bueno-Beti, C., Lim, C. X., Protonotarios, A., Szabo, P. L., Westaby, J., Mazic, M., Sheppard, M. N., Behr, E., Hamza, O., Kiss, A., Podesser, B. K., Hengstschläger, M., Weichhart, T., & Asimaki, A. (2023). An mTORC1‐Dependent Mouse Model for Cardiac Sarcoidosis. Journal of the American Heart Association. https://doi.org/10.1161/jaha.123.030478

Vancouver

Bueno-Beti C, Lim CX, Protonotarios A, Szabo PL, Westaby J, Mazic M, et al. An mTORC1‐Dependent Mouse Model for Cardiac Sarcoidosis. Journal of the American Heart Association. 2023. doi:10.1161/jaha.123.030478

BibTeX
@article{BuenoBeti2023,
  author = {Bueno-Beti, Carlos and Lim, Clarice X and Protonotarios, Alexandros and Szabo, Petra Lujza and Westaby, Joseph and Mazic, Mario and Sheppard, Mary N and Behr, Elijah and Hamza, Ouafa and Kiss, Attila and Podesser, Bruno K and Hengstschläger, Markus and Weichhart, Thomas and Asimaki, Angeliki},
  title = {An mTORC1‐Dependent Mouse Model for Cardiac Sarcoidosis},
  journal = {Journal of the American Heart Association},
  year = {2023},
  doi = {10.1161/jaha.123.030478}
}
Kostenlos starten →